Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Signal Transduction and Cytokines

Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway

Leukemia volume 19, pages 1605–1612 (2005)Cite this article

Abstract

17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of the molecular chaperone heat shock protein 90, results in cell type-specific inhibition of proliferation of leukemic cells. GTP14564 is a tyrosine kinase inhibitor actively against FLT3. The current study evaluated the single and combined effects of 17-AAG and GTP14564, and the role of FLT3 in their inhibitory effects. The importance of FLT3 mutations was demonstrated using small interfering RNA (siRNA) targeted to FLT3. Similar to FLT3 siRNA, GTP14564 inhibited FLT3 internal tandem duplication (ITD) cells (MV4;11) and FLT3 amplified wild-type cells (SEMK2-M1), but not wild-type FLT3 cells (RS4;11). However, when RS4;11 cells were stimulated with FLT3-ligand, phosphorylation of STAT5 and GTP14564 inhibition were observed. Responses to GTP14564 in all cell types were directly related to the level of STAT5 phosphorylation in the cells. We observed synergistic effects of combined 17-AAG and GTP14564 in cell lines with FLT3-ITD and amplified wild-type FLT3. Combined treatment with 17-AAG and GTP14564 reduced the levels of p-FLT3 and p-STAT5, enhanced G0/G1 arrest and apoptosis in FLT3-ITD and amplified wild-type FLT3. The combination of 17-AAG with FLT3 kinase inhibitors can enhance targeted therapy in leukemias with FLT3 mutations, such as MLL fusion gene leukemias.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 20: 41–47.

    Google Scholar 

  2. Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542.

    Article  CAS  Google Scholar 

  3. Sawyers CL . Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002; 1: 413–415.

    Article  CAS  Google Scholar 

  4. Stirewalt DL, Radich JP . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650–665.

    Article  CAS  Google Scholar 

  5. Levis M, Small D . FLT3: ITDoes matter in leukemia. Leukemia 2003; 17: 1738–1752.

    Article  CAS  Google Scholar 

  6. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173–183.

    Article  CAS  Google Scholar 

  7. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9: 5465–5476.

    CAS  PubMed  Google Scholar 

  8. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885–3891.

    Article  CAS  Google Scholar 

  9. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421–432.

    Article  CAS  Google Scholar 

  10. Yee KW, O’Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002; 100: 2941–2949.

    Article  CAS  Google Scholar 

  11. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–3605.

    Article  CAS  Google Scholar 

  12. Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 2003; 278: 32892–32898.

    Article  CAS  Google Scholar 

  13. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002; 16: 1535–1540.

    Article  CAS  Google Scholar 

  14. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH . FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003; 9: 4483–4493.

    CAS  PubMed  Google Scholar 

  15. Neckers L . Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: S55–S61.

    Article  CAS  Google Scholar 

  16. Munster PN, Basso A, Solit D, Norton L, Rosen N . Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001; 7: 2228–2236.

    CAS  PubMed  Google Scholar 

  17. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003; 63: 8420–8427.

    CAS  PubMed  Google Scholar 

  18. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N . Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003; 63: 2139–2144.

    CAS  PubMed  Google Scholar 

  19. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ . Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res 2003; 63: 3241–3246.

    CAS  PubMed  Google Scholar 

  20. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P et al. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 2003; 102: 1824–1832.

    Article  CAS  Google Scholar 

  21. George P, Bali P, Cohen P, Tao J, Guo F, Sigua C et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004; 64: 3645–3652.

    Article  CAS  Google Scholar 

  22. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W . Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003; 9: 2140–2150.

    CAS  PubMed  Google Scholar 

  23. Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J . Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003; 102: 646–651.

    Article  CAS  Google Scholar 

  24. Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R et al. Essential role of signal transducer and activator of transcription Stat5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000; 192: 719–728.

    Article  CAS  Google Scholar 

  25. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E . Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001; 15: 1923–1931.

    Article  CAS  Google Scholar 

  26. Dykxhoorn DM, Novina CD, Sharp PA . Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4: 457–467.

    Article  CAS  Google Scholar 

  27. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004; 103: 1085–1088.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Supported in part from a grant from the National Cancer Institute (CA087053) to JK and the Childrens Cancer Research Fund to JK.

Author information

Author notes

  1. R Nishiuchi

    Present address: Kochi Health Sciences Center, 2125-1 IKE, Kochi, 780-8555, Japan

Authors and Affiliations

  1. The Cancer Center, University of Minnesota, Minneapolis, MN, USA

    Q Yao, R Nishiuchi & J H Kersey

  2. The Division of Cellular Therapy, Institute of Medical Science, University of Tokyo, Tokyo, Japan

    T Kitamura

Authors
  1. Q Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Nishiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J H Kersey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J H Kersey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yao, Q., Nishiuchi, R., Kitamura, T. et al. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. Leukemia 19, 1605–1612 (2005). https://doi.org/10.1038/sj.leu.2403881

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403881

Keywords

This article is cited by

Search

Advanced search

Quick links